ArticlePulmonary circulation
Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions?
Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07119658 (Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Association of post-thrombotic syndrome with metabolic syndrome and inflammation - a systematic review.Frontiers in immunology · 2025Pooled it
- Article
- Exploring the pathogenesis of pulmonary vascular disease.Frontiers in medicine · 2024Review
- Respiratory issues in patients with multiple sclerosis as a risk factor during SARS-CoV-2 infection: a potential role for exercise.Molecular and cellular biochemistry · 2023Review
- Respiratory complications of obesity: from early changes to respiratory failure.Breathe (Sheffield, England) · 2023Review
- Pulmonary hypertension and insulin resistance: a mechanistic overview.Frontiers in endocrinology · 2023Review
- TGF-β: The missing link in obesity-associated airway diseases?Current research in pharmacology and drug discovery · 2021Review
- The "Super-Fontan" Phenotype: Characterizing Factors Associated With High Physical Performance.Frontiers in cardiovascular medicine · 2021Article
- Metabolic Syndrome Increases Risk of Venous Thromboembolism Recurrence after Acute Pulmonary Embolism.Annals of the American Thoracic Society · 2020Article
- Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice.Respiratory research · 2020Article
- Effect of metabolic syndrome on mean pulmonary arterial pressures in patients with acute pulmonary embolism treated with catheter-directed thrombolysis.International journal of cardiology · 2020Article
- Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis.Blood advances · 2020Article
- Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2019Review
- Pulmonary Hypertension and Obesity: Focus on Adiponectin.International journal of molecular sciences · 2019Review
- Pulmonary vascular dysfunction in metabolic syndrome.The Journal of physiology · 2019Review
- Single Microfluidic Electrochemical Sensor System for Simultaneous Multi-Pulmonary Hypertension Biomarker Analyses.Scientific reports · 2017Article
- Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target.Scientific reports · 2017Article
- Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.British journal of pharmacology · 2017Review
- Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.World journal of gastroenterology · 2016Review
- Metabolic Dysfunction in Pulmonary Arterial Hypertension.Current hypertension reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a condition of unknown etiology whose pathological features include increased vascular resistance, perivascular inflammatory cell infiltration and pulmonary arteriolar remodeling. Although risk factors for PAH are poorly defined, recent studies indicate that obesity may be an important risk factor for this condition. The mechanisms leading to this association are largely unknown, but bioactive mediators secreted from adipose tissue have been implicated in this process. One of the most important mediators released from adipose tissue is the adipokine adiponectin. Adiponectin is highly abundant in the circulation of lean healthy individuals, and possesses well-described metabolic and antiinflammatory actions. Levels of adiponectin decrease with increasing body mass, and low levels are directly linked to the development of PAH in mice. Moreover, overexpression of adiponectin has been shown to protect mice from developing PAH in response to inflammation and hypoxia. Based on the findings from these studies, it is suggested that the effects of adiponectin are mediated, in part, through its antiinflammatory and antiproliferative properties. In this review, we discuss the emerging evidence demonstrating a role for adiponectin in lung vascular homeostasis and discuss how deficiency in this adipocyte-derived hormone might explain the recent association between obesity and PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.